###### Strengths and limitations of this study

-   Reducing the default dispense quantity for new opioid analgesic prescriptions in the electronic health record is a novel intervention with the potential for widespread implementation and scale-up.

-   A cluster randomised controlled trial will provide rigorous evidence for or against efficacy.

-   Consideration of unintended consequences such as prescription reorders and increased health service utilisation will provide additional information on the impact of the intervention

-   The setting of the trial (a single urban medical centre, with multiple, diverse clinics) may limit generalisability.

-   Lack of access to data (ie, prescriptions and visits) at outside institutions may lead to measurement error for some outcomes.

Introduction {#s1}
============

In the USA, opioid consumption, opioid use disorder and fatal overdoses involving opioids have increased rapidly. Between 1999 and 2015, sales of opioid analgesics tripled.[@R1] In 2015, 33 091 individuals died of a drug overdose involving opioids.[@R2] Beyond the human cost, the economic cost of opioid use disorder and overdose is estimated to be almost US\$80 billion (2015 US\$) annually.[@R3]

While most research aiming to reduce morbidity and mortality from opioid analgesics focuses on people with chronic pain, opioid analgesics for acute non-cancer pain are also associated with significant personal and public health risk. Fatal and non-fatal overdoses occur among people with new or short-term opioid analgesic prescriptions.[@R4] Furthermore, up to 72% of people prescribed opioid analgesics have tablets left over, and most plan to keep them.[@R6] Leftover tablets are often misused, diverted or accidentally ingested by household members (eg, children) and are a contributor to overdose mortality beyond the index patient.[@R9] Previous interventions to reduce opioid analgesic prescribing for acute pain have included provider education or promulgation of guidelines; however, these interventions can be labour intensive and may only have short-lived effects. In addition, as of December 2017, at least 24 states have passed laws setting limits on opioid analgesic prescriptions[@R14]; however, enforcement mechanisms are often unclear and the impact of such laws on prescribing is not known.

Environmental or structural interventions, such as modifying default prescribing options, have the potential to change provider behaviour. Defaults can have powerful effects, including in healthcare settings.[@R15] For opioid analgesic prescriptions, this would take the form of reducing the default dispense quantity (ie, the default number of tablets to dispense) for all new prescriptions. While providers can modify the number of tablets actually prescribed, default options can alter practice. For example, within the electronic health record (EHR), changing prescription defaults from brand name to generic increased generic prescribing significantly.[@R16] In one recent study involving opioid analgesics, *removing* the existing default dispense quantity for two types of opioid analgesics was associated with a modestly higher mean number of tablets dispensed and an increase in the variability of prescriptions, relative to preintervention.[@R17] While these studies suggest that defaults can alter opioid analgesic prescribing behaviour, the impact of reducing the default dispense quantity to encourage reductions in opioid analgesic prescribing has not been rigorously studied.

While reducing the default dispense quantity for new opioid analgesic prescriptions has the potential to reduce the quantity prescribed for acute pain, any reduction may be offset, at least in part, by the potential for unintended consequences. These can include an increased need for prescription reorders, medical visits due to inadequately treated pain, or both. However, the large proportion of patients with leftover opioid analgesic tablets suggests that reductions in the quantity prescribed will simply move towards aligning prescriptions with what patients actually take for the acute episode of pain.[@R6]

The goal of this study is to investigate the impact of a uniform, reduced, default dispense quantity for new opioid analgesic prescriptions on the quantity prescribed for acute pain. We will test this intervention in a cluster randomised controlled trial in 32 primary care sites and four emergency departments (ED), responsible for over 13 000 new opioid analgesic prescriptions annually. We hypothesise that, compared with control, reducing the default dispense quantity will lead to a higher percentage of prescriptions written for the new, reduced default number of tablets or fewer. In addition, compared with control, we hypothesise that reducing the default dispense quantity will not lead to a significant increase in opioid analgesic prescription reorders or primary care visits, ED visits or hospitalisations.

Methods and analysis {#s2}
====================

Study setting {#s2a}
-------------

Montefiore Medical Center (Montefiore) is the largest healthcare system in The Bronx (a borough of New York City) and provides comprehensive primary, specialty, surgical and emergency care at 4 hospitals, 4 EDs and over 40 ambulatory clinics, with over 3 million patient visits annually. Montefiore is also a major integrated healthcare delivery system, administering federal (ie, managed Medicaid and Medicare) and private insurance plans and coordinating care for approximately 225 000 individuals. For this study, we have selected the ambulatory settings in which opioid analgesic prescribing is common: primary care practices and EDs.

Eligibility criteria {#s2b}
--------------------

### Primary care and ED sites {#s2b1}

We will include all primary care (n=32) and (n=4) ED sites within Montefiore. Primary care sites can be designated as internal medicine, family medicine or urgent care.

### Provider participants {#s2b2}

As the intervention is a modification to the EHR, the primary participants are Montefiore providers. Eligible providers will include those who provide adult primary care or ED care.

### Patient participants {#s2b3}

We will analyse outcomes for patients who: (A) received a *new* opioid analgesic prescription, defined as no other opioid analgesic prescription of any type in the preceding 6 months (a definition used in previous cohort studies)[@R18]; (b) aged ≥18 years; and (C) no International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis code for cancer within 1 year prior to the new opioid analgesic prescription. For patients receiving more than one new opioid analgesic prescription during the study period, we will only include the first prescription.

Intervention and control conditions {#s2c}
-----------------------------------

The intervention condition is a site-level change to the EHR to implement a uniform, reduced, default dispense quantity for new opioid analgesic prescriptions. The number of tablets actually prescribed will be *fully modifiable* by providers who can tailor the prescription based on clinical factors. The intervention will include all short-acting opioid analgesics commonly used to treat acute pain: immediate-release oxycodone, immediate-release hydrocodone, tramadol and codeine. We will include all brand and generic formulations and all tablet strengths and coformulations with acetaminophen.

We have chosen 10 tablets as the default dispense quantity for all medication products included in the intervention condition. For opioid analgesics, there are no specific studies addressing the optimal quantity that minimises the risks of harms while adequately treating pain. Generally, guidelines recommend a limited duration with early reassessment.[@R20] While medications included in the intervention are typically written for a range of one to two tablets every 4--6 hours, as needed, patients may only take between one and three tablets per day total.[@R23] We chose a default of 10 tablets because we believe it represents at least a 3--5 day supply for most patients.

The usual EHR will serve as the control condition. Depending on the exact medication product, the pre-existing default number of tablets is typically 30 or blank, with several outliers ([table 1](#T1){ref-type="table"}). These pre-existing defaults are a mixture of those preloaded in the base installation of our EHR and those created by our institution when generating defaults for commonly prescribed medications. While most products have a pre-existing default, some do not (ie, the 'quantity dispensed' field is blank). Therefore, while the intervention will reduce the default dispense quantity for most products, it will create a default dispense quantity for some.

###### 

Pre-existing default dispense quantity for short-acting opioid analgesics included in the intervention\*

  Opioid ingredient                                Product name and strength                      Primary care sites   Emergency department sites
  ------------------------------------------------ ---------------------------------------------- -------------------- ----------------------------
  Oxycodone                                        Oxycodone 5 mg tablet                          30                   30
  Oxycodone 5 mg capsule                           30                                             30                   
  Oxycodone 10 mg tablet                           Blank                                          Blank                
  Oxycodone 15 mg tablet                           30                                             30                   
  Oxycodone 20 mg tablet                           Blank                                          Blank                
  Oxycodone 30 mg tablet                           30                                             30                   
  Roxicodone 5 mg tablet                           20                                             20                   
  Roxicodone 15 mg tablet                          30                                             30                   
  Roxicodone 30 mg tablet                          30                                             30                   
  Oxycodone-acetaminophen 2.5 mg-325 mg tablet     30                                             30                   
  Oxycodone-acetaminophen 5 mg-325 mg tablet       Blank                                          Blank                
  Oxycodone-acetaminophen 7.5 mg-325 mg tablet     30                                             30                   
  Oxycodone-acetaminophen 10 mg-325 mg tablet      30                                             30                   
  Percocet 2.5 mg-325 mg tablet                    30                                             30                   
  Percocet 5 mg-325 mg tablet                      Blank                                          Blank                
  Percocet 7.5 mg-325 mg tablet                    20                                             20                   
  Percocet 10 mg-325 mg tablet                     20                                             20                   
  Endocet 2.5 mg-325 mg tablet                     30                                             30                   
  Endocet 5 mg-325 mg tablet                       Blank                                          Blank                
  Endocet 7.5 mg-325 mg tablet                     30                                             30                   
  Endocet 10 mg-325 mg tablet                      30                                             30                   
  Hydrocodone                                      Hydrocodone-acetaminophen 5 mg-300 mg tablet   112                  112
  Hydrocodone-acetaminophen 5 mg-325 mg tablet     50                                             30                   
  Hydrocodone-acetaminophen 7.5 mg-300 mg tablet   180                                            180                  
  Hydrocodone-acetaminophen 7.5 mg-325 mg tablet   50                                             30                   
  Hydrocodone-acetaminophen 10 mg-300 mg tablet    180                                            180                  
  Hydrocodone-acetaminophen 10 mg-325 mg tablet    30                                             30                   
  Lortab 5 mg-325 mg tablet                        30                                             30                   
  Lortab 7.5 mg-325 mg tablet                      30                                             30                   
  Lortab 10 mg-325 mg tablet                       30                                             30                   
  Norco 5 mg-325 mg tablet                         30                                             30                   
  Norco 7.5 mg-325 mg tablet                       30                                             30                   
  Norco 10  mg-325 mg tablet                       30                                             30                   
  Tramadol                                         Tramadol 50 mg tablet                          Blank                Blank
  Ultram 50 mg tablet                              90                                             20                   
  Tramadol-acetaminophen 37.5  mg-325 mg tablet    30                                             30                   
  Ultracet 37.5  mg-325 mg tablet                  30                                             30                   
  Codeine                                          Codeine sulfate 15 mg tablet                   30                   30
  Codeine sulfate 30 mg tablet                     30                                             30                   
  Acetaminophen-codeine 300-15 mg tablet           30                                             30                   
  Acetaminophen-codeine 300-30 mg tablet           Blank                                          15                   
  Acetaminophen-codeine 300-60 mg tablet           30                                             30                   
  Tylenol/codeine \#3 300-30 mg tablet             Blank                                          Blank                
  Tylenol/codeine \#4 300-60 mg tablet             30                                             30                   

\*Pre-existing defaults are a mixture of those preloaded in the base installation of the electronic health record system and those created by our institution when generating defaults for commonly prescribed medications.

Outcomes {#s2d}
--------

To determine the impact of the intervention, we will analyse patient-level outcomes. Therefore, the unit of inference is the patient. We will collect outcome data from 6 months prior to intervention implementation to 18 months after implementation.

### Primary outcome {#s2d1}

*Quantity of opioid analgesics.* This outcome refers to the quantity prescribed in each new opioid analgesic prescription. We will use three measures of the primary outcome:*≤10 tablets (primary measure, dichotomous).* We will classify all prescriptions as greater than or less than/equal to 10 tablets (the default). This outcome is relevant specifically to the impact of the intervention.*Number of tablets to dispense (continuous).* This outcome is relevant to accidental ingestion and diversion (ie, the number of tablets available for consumption).*Total morphine milligram equivalents (MME) to dispense (continuous).* The use of MME standardises comparisons between different types of opioid analgesics with different strengths and potencies.[@R26] Overdose risk increases with increasing MME[@R4] so this measure is relevant to overdose risk.

### Secondary outcomes {#s2d2}

1.  *Opioid analgesic prescription reorders within 30 days of the initial prescription.* Such reorders can occur if patients do not receive an adequate supply of opioid analgesics to treat their pain in the initial prescription and contact their providers to obtain more. Measured as: (A) any reorder (*y/n*); (B) number of tablets; and (C) MME.

2.  *Health service utilisation within 30 days of the initial prescription*. Medical visits can occur if patients experience an opioid-related adverse event (eg, delirium) or intractable pain (eg, from not enough medication). We will analyse primary care visits, ED visits and hospitalisations for any reason.

Provider and patient characteristics (covariates) {#s2e}
-------------------------------------------------

In addition to primary and secondary outcomes, we will collect additional data on providers and patients. We have selected variables that are likely to be confounders. For providers, we will collect sex and years since graduation from medical school. For patients, we will collect demographic information (age, sex and race/ethnicity as recorded in the EHR). We will also collect the pain diagnosis at the visit where the initial opioid analgesic was prescribed (ie, the indication for the opioid analgesic) in addition to the presence or absence of a history of psychiatric illness and a history of substance use disorder within the 1 year preceding the initial opioid analgesic prescription. For pain diagnoses, we will group ICD-10-CM diagnosis codes into clinically meaningful categories based on the diagnostic categories outlined in the US Department of Health and Human Services National Pain Strategy.[@R29] For history of psychiatric illness and history of substance use disorder, we will use existing diagnosis code groupings produced by the Healthcare Cost and Utilization Project, sponsored by the Agency for Healthcare Research and Quality of the US Department of Health and Human Services.[@R30]

Randomisation {#s2f}
-------------

The unit of randomisation will be the site (ie, cluster randomisation). Compared with randomisation at the level of the provider (ie, individual-level randomisation), randomisation of sites would be expected to reduce statistical efficiency due to correlated outcomes within clusters.[@R31] However, we chose site-level randomisation instead of provider-level randomisation to reduce contamination and to potentially increase the intervention's effectiveness via peer effects.[@R32] At Montefiore, the vast majority of providers only practise at one site. In addition, technical limitations of Montefiore's EHR (Epic) render provider-level randomisation less feasible.

Study sites differ greatly in visit volume and characteristics; therefore, we will randomise in matched pairs to avoid a major imbalance which could threaten study validity. For randomisation, we will stratify sites by type (ie, primary care vs ED). Further, within primary care sites, prescribing patterns and the intervention's impact may differ by specialty (ie, internal medicine and family medicine) and whether the site is a training site for resident physicians. Therefore, we will stratify on these variables as well. Within strata, we will use optimal non-bipartite matching to pair sites based on the number of new opioid analgesic prescriptions, the number of visits and the percentage of patients with commercial insurance.[@R34] For ED sites, given the very large differences in visit volume, we will divide the four sites into a 'pair' consisting of the largest ED versus the three other smaller EDs combined.

Blinding {#s2g}
--------

Randomisation of sites within pairs will be conducted by the study statistician and provided directly to the health information technology department. Other study investigators will therefore be blind to randomisation assignment.

Data collection and management {#s2h}
------------------------------

We will obtain provider data from our institution's internal provider directory as well as publicly accessible medical license data from New York State. We will obtain all patient data from Montefiore's EHR. Study data will be stored in an encrypted, password-protected database only accessible to study investigators.

Statistical analysis {#s2i}
--------------------

We will conduct analyses at two time points, 6 months after intervention implementation and 18 months after intervention implementation. Using a difference-in-differences (DID) analysis, we will determine the impact of the intervention by comparing the change in outcomes in the intervention group with the change in outcomes in the control group.[@R35] For example, for the 6-month analysis, we will compare the change in the intervention group's outcomes from −6 months to +6 months to the change in the control group's outcomes from −6 months to +6 months.

A DID analysis has advantages. First, while we can include covariates to adjust for imbalance in site, provider and patient characteristics between intervention and control groups, DID accounts for residual time-invariant group-level heterogeneity such as differences in baseline outcome levels and hard-to-measure factors like overall quality of care between intervention and control sites.[@R36] Second, DID will allow us to account for prescribing changes due to factors other than the intervention (eg, state or city policies aimed at reducing prescribing). For example, in July 2016, New York State enacted a law limiting opioid analgesic prescriptions for acute pain to a 7-day supply.

A DID analysis also relies on several assumptions which we will examine.[@R36] First, we will assess whether trends in outcomes were parallel between the intervention and control sites prior to the intervention. For this analysis, in the preintervention period, we will determine the significance of an interaction term between study allocation (intervention/control) and month. Second, to determine the composition of the intervention and the control sites, we will calculate and report descriptive statistics for both provider and patient characteristics, preintervention and postintervention. Finally, we will examine the potential for contamination of the arms. Although we expect the number of providers who write prescriptions at both an intervention and a control site will be low, we will determine the number of such providers and report it.

We will conduct the main DID analysis using generalised linear mixed regression models. We will include a variable indicating time (preintervention/postintervention) and a variable indicating study allocation (intervention/control). In DID, the interaction of these two variables is the parameter of interest. To adjust for potential changes in composition over time, we will include relevant site characteristics (number of new opioid analgesic prescriptions, the number of visits and percentage of patients with commercial insurance), provider characteristics (sex and years since medical school graduation) and patient characteristics (age, sex, race/ethnicity, pain diagnosis, history of substance use disorder, history of psychiatric disorder) as covariates in all models. To account for the nesting of patients within providers and providers within sites, we will include random intercepts both at the provider level and at the matched site pair level. For all estimates, we will calculate heteroscedasticity robust (empirical) SEs.[@R38]

For each outcome, we will explore the distribution of the outcome variable and potential transformations to determine the appropriate regression models (eg, binomial, linear, Poisson or negative binomial). When analysing the impact of the intervention at 18 months, we will identify any change in the intervention's impact after 6 months (ie, whether it decays over time) by using the 0--6 month postintervention period as the referent.

In addition to the main analysis, we will conduct several exploratory subgroup analyses. We will analyse the impact of the intervention stratified by site type (ie, primary care vs ED) and by medication type (eg, schedule II vs schedules III and IV). We will also perform separate analyses on products where the pre-existing default was reduced and products where there was no pre-existing default (ie, the pre-existing 'quantity dispensed' field was blank).

Finally, we intend to explore other analyses examining the precise timing of any changes in outcomes (eg, immediate or delayed) and to characterise the heterogeneity of the intervention's effect between matched pairs. Such analyses will be defined post hoc and are subject to availability of resources such as additional statistical support and technical considerations such as convergence of relevant statistical models.

Sample size {#s2j}
-----------

From preliminary data analyses, we estimate eligible providers (n=\~17 per site) will write a total of approximately 7000 new opioid analgesic prescriptions (n=\~11 prescriptions per provider) from the 36 sites during a 6-month postintervention period. And, in the baseline period (ie, 6 months prior), 32.7% of prescriptions will be for ≤10 tablets. From these parameters, we estimated the minimal detectable difference between study arms using a three-level hierarchical model (ie, patients clustered within providers who are clustered within matched site pairs). Because the intracluster correlation coefficient (ICC) is not known, we used a range of ICC from 0.01 to 0.1 at the patient level; only this level of ICC is needed for power analysis under our study design.[@R40] Because any change in outcomes in the control arm is also unknown, we used a range of increases in the percentage of prescriptions for ≤10 tablets in the control arm of 0--10 percentage points. Within this range of ICC, change in control arm outcomes, alpha=0.05 and power ≥80%, this study will be powered to detect a change in the intervention arm, over and above any change in the control arm, of 4.4--4.7 percentage points.

Timeline and monitoring {#s2k}
-----------------------

We randomised sites and implemented the new default dispense quantity for the intervention arm on 13 December 2016. Before this change, primary care sites had the same EHR for approximately 19 months. Two ED sites had the same EHR for 11 months and two ED sites had the same EHR system for 7 months (ie, those sites implemented the current EHR just before start of the 6-month preintervention period).

The principal investigator (MBa) will oversee data and safety monitoring, including review of any protocol deviations (eg, unplanned changes to the EHR) and submission of an annual progress report to the Montefiore Medical Center/Albert Einstein College of Medicine Institutional Review Board and the study funder (The National Institute on Drug Abuse of the National Institutes of Health). As this study evaluates an EHR modification using data collected directly from the EHR, study investigators will not have direct contact with any human subjects. Because of the low-risk nature of the intervention, we will not convene a formal Data Safety and Monitoring Board and will not conduct planned audits.

Limitations {#s2l}
-----------

This study has limitations. First, we will only able to obtain data from within our medical centre, outside prescriptions and visits will not be captured. Therefore, we may underestimate the number of opioid analgesic reorders and the degree of health service utilisation. Further, this may bias the study findings if patients in one arm are more likely to obtain follow-up care at Montefiore than patients in the other arm. Second, as our main data source is the EHR, we do not have information on whether prescriptions were actually dispensed and our outcome measures are limited to those recorded in the course of routine clinical care. To address this limitation, we are planning to conduct a telephone survey of patients to understand patient-reported outcomes such as pain, functioning and patient satisfaction.

Ethics and dissemination {#s2m}
------------------------

This trial was approved by the Montefiore Medical Center/Albert Einstein College of Medicine Institutional Review Board (IRB number: 2016-6036). This trial was also granted a waiver of informed consent, similar to previous studies of EHR-based provider interventions.[@R41] During data collection and analysis, all data collected for this study will be deidentified at the earliest possible opportunity and stored in an encrypted and password-protected database. At the conclusion of the trial, we will investigate the feasibility of depositing deidentified data in a publicly accessible repository that maintains confidentiality.

We will disseminate the results of this study through peer-reviewed publications, presentations at scientific conferences, and meetings with key stakeholders including health system leadership. Reporting of results will be in accordance with the Consolidated Standards of Reporting Trials extension to cluster randomised trials.[@R43]
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